Secondary analysis of the phase 3 ELEVATE UC trials in ulcerative colitis: etrasimod vs placebo partially reduced circulating T- and B-cell subsets at week 12, with mucosal falls in T and B cells, myeloid cells and neutrophils; monocytes and NK cells were not affected.
Secondary analysis
Siegmund et al. Etrasimod reduces circulating and mucosal inflammatory lymphocyte populations and alters innate immune and non-immune cell signatures in intestinal mucosa: ELEVATE UC phase 3 clinical data